(Q44019739)

29 November 2017

title

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. (English)

1 reference

29 November 2017

1 reference

4

Ronald N Jones

1 reference

29 November 2017

Alan H Mutnick

1

1 reference

29 November 2017

Douglas J Biedenbach

series ordinal

2

1 reference

29 November 2017

John D Turnidge

series ordinal

3

1 reference

29 November 2017

publication date

1 May 2002

1 reference

Diagnostic Microbiology and Infectious Disease

29 November 2017

published in

1 reference

29 November 2017

volume

43

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

65-73

1 reference

Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Linezolid for the treatment of resistant gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Surveillance of antimicrobial resistance--what, how and whither?

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Novelties in the field of anti-infectives in 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Novelties in the field of anti-infective compounds in 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Linezolid: an oxazolidinone antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900371-1

7 January 2021

10.1016/S0732-8893(02)00371-1

Identifiers

DOI

1 reference

29 November 2017

1 reference